Inhibitors of renal sodium/glucose cotransporter 2 (SGLT2) are new anti-hyperglycaemic drugs that reduce proximal tubular glucose and sodium reabsorption. The Canagliflozin Cardiovascular Assessment Study (CANVAS) Program is the second major trial to demonstrate beneficial effects of SGLT2 inhibitors on the kidney and cardiovascular system in patients with type 2 diabetes mellitus.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Postprandial Effects on ENaC-Mediated Sodium Absorption
Scientific Reports Open Access 12 March 2019
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Coca, S. G., Ismail-Beigi, F., Haq, N., Krumholz, H. M. & Parikh, C. R. Role of intensive glucose control in development of renal end points in type 2 diabetes mellitus: systematic review and meta-analysis intensive glucose control in type 2 diabetes. Arch. Intern. Med. 172, 761–769 (2012).
Wanner, C. et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N. Engl. J. Med. 375, 323–334 (2016).
Zinman, B. et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N. Engl. J. Med. 373, 2117–2128 (2015).
Neal, B. et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N. Engl. J. Med. http://dx.doi.org/10.1056/NEJMoa1611925 (2017).
Khunti, K. et al. Hypoglycemia and risk of cardiovascular disease and all-cause mortality in insulin-treated people with type 1 and type 2 diabetes: a cohort study. Diabetes Care 38, 316–322 (2015).
Ferrannini, E., Mark, M. & Mayoux, E. CV protection in the EMPA-REG OUTCOME trial: a “thrifty substrate” hypothesis. Diabetes Care 39, 1108–1114 (2016).
Mudaliar, S., Alloju, S. & Henry, R. R. Can a shift in fuel energetics explain the beneficial cardiorenal outcomes in the EMPA-REG OUTCOME study? A Unifying Hypothesis. Diabetes Care 39, 1115–1122 (2016).
Vallon, V. & Thomson, S. C. Renal function in diabetic disease models: the tubular system in the pathophysiology of the diabetic kidney. Annu. Rev. Physiol. 74, 351–375 (2012).
Vallon, V. & Thomson, S. C. Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition. Diabetologia 60, 215–225 (2017).
O'Bryan, G. T. & Hostetter, T. H. The renal hemodynamic basis of diabetic nephropathy. Semin. Nephrol. 17, 93–100 (1997).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
Over the past 36 months, V.V. has served as a consultant and received honoraria from Bayer, Boehringer Ingelheim, Intarcia Therapeutics, Astra-Zeneca, Janssen Pharmaceutical, Eli Lilly and Merck, and received grant support for investigator-initiated research from Astra-Zeneca, Bayer, Boehringer Ingelheim, Fresenius, and Janssen. Over the past 36 months, S.C.T. has received research support from Merck and Pfizer. These companies were not involved in the development or writing of this commentary.
PowerPoint slides
Rights and permissions
About this article
Cite this article
Vallon, V., Thomson, S. Cardiovascular and renal benefits of SGLT2 inhibition: insights from CANVAS. Nat Rev Nephrol 13, 517–518 (2017). https://doi.org/10.1038/nrneph.2017.113
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrneph.2017.113
This article is cited by
-
Postprandial Effects on ENaC-Mediated Sodium Absorption
Scientific Reports (2019)
-
Role of TRPC6 in Progression of Diabetic Kidney Disease
Current Hypertension Reports (2019)
-
The Potential Role of SGLT2 Inhibitors in the Treatment of Type 1 Diabetes Mellitus
Drugs (2018)